Michael J. Pellini

Michael Pellini, M.D., is a Managing Partner of Section 32, a tech and life-science-based venture capital fund. He served as CEO of Foundation Medicine (NASDAQ:FMI) from May 2011 until he transitioned to Chairman in February 2017 through the close of Roche’s (NASDAQ:RHHBY) acquisition of FMI in August 2018. He was President and COO of Clarient, Inc. (“Clarient”), which was acquired by GE Healthcare in 2010. He also currently serves as a member of the Board of Directors for Tango Therapeutics, Singular Genomics, the Personalized Medicine Coalition, and the Mission Hospital Foundation. As a physician with more than 20 years of executive experience with companies at the forefront of clinical diagnostics and genomics, Dr. Pellini brings a breadth of understanding in personalized medicine, with a particular interest and focus in cancer. Dr. Pellini is a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health, as well as the Advisory Board for Mission Hospital’s Cancer Institute (Provident/St. Joseph Health). Dr. Pellini received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.

Michael J. Pellini is the Managing Partner at Section 32, based in United States, North America. With a background in Financial Services, Michael J. Pellini has a rich history of leadership and innovation. Michael J. Pellini studied BA unknown @ Boston College. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.